Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I b study evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics of the dry powder formulation of INNA-051 in older adults

Next Previous
Trial Profile

Phase I b study evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics of the dry powder formulation of INNA-051 in older adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INNA-051 (Primary)
  • Indications COVID 2019 infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 02 Apr 2025 According to an ENA Respiratory media release, company announces today the early view publication of results of a Phase I extension study in older adults (66-80) of its liquid formulation of INNA-051 in ERJ Open Research, a leading research journal of the European Respiratory Society.
  • 22 Jan 2025 Results of Thirty-two participants aged 60 or over were enrolled in the study, presented in the ENA Respiratory media release Media Release.
  • 22 Jan 2025 According to an ENA Respiratory media release, company announced that it has successfully completed dosing of the older adult cohorts in its Phase Ib study of INNA-051. and The DOD-funded extension to assess safety, tolerability and pharmacodynamics of the new formulation in younger adults aged 18-45 is ongoing and will complete dosing later in January, With Complete reporting of the study is expected in Q2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top